Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Thursday

Sutro Biopharma (NASDAQ:STRO) is expected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($4.66) per share and revenue of $9.2630 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Sutro Biopharma Stock Performance

Shares of Sutro Biopharma stock opened at $24.98 on Tuesday. The stock has a market cap of $212.58 million, a P/E ratio of -0.96 and a beta of 1.47. The stock’s fifty day moving average is $15.86 and its 200 day moving average is $11.62. Sutro Biopharma has a one year low of $5.23 and a one year high of $26.54.

Wall Street Analyst Weigh In

A number of analysts have commented on STRO shares. Wedbush restated a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. HC Wainwright lifted their price target on shares of Sutro Biopharma to $10.00 and gave the company a “neutral” rating in a report on Monday, December 22nd. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Finally, Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective on the stock in a research report on Tuesday, January 20th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $31.83.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds have recently modified their holdings of STRO. Velan Capital Investment Management LP grew its stake in Sutro Biopharma by 2.0% during the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock valued at $2,709,000 after acquiring an additional 60,000 shares in the last quarter. UBS Group AG lifted its stake in Sutro Biopharma by 14.0% in the 3rd quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock worth $1,602,000 after purchasing an additional 226,955 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Sutro Biopharma by 1,052.8% during the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Sutro Biopharma during the second quarter valued at about $492,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Sutro Biopharma in the third quarter worth about $387,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.